latest update:
[TrialBase DB]

trial summary · NCT07892027

Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy

Phase II Trial of Natalizumab for Prevention of Immune Effector Cell Associated Neurologic Syndrome (ICANS) in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy for B-Cell Hematologic Malignancies

Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Diffuse Large B-Cell Lymphoma, sponsored by University of Michigan Rogel Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07892027phase PHASE2enrollment 26start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase II studies how well natalizumab works in preventing immune effector cell associated neurologic syndrome (ICANS) in patients with diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) receiving chimeric antigen receptor (CAR) T-cell therapy. A major complication of CAR T-cell therapy is ICANS. ICANS is inflammation of the brain or nerves. ICANS currently requires high-dose corticosteroid treatment which can inhibit CAR T-cell response. Natalizumab prevents immune cells from traveling from the blood to the fluid around the brain, which is a process thought to play a major role in CAR T-cell related brain injury. Natalizumab may be safe and effective in decreasing the frequency of severe ICANS in patients with DLBCL or MCL receiving CAR T-cell therapy.

Source record: https://clinicaltrials.gov/study/NCT07892027

Facts

registry idNCT07892027
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionRecurrent Diffuse Large B-Cell Lymphoma
sponsorUniversity of Michigan Rogel Cancer Center
sponsor classOTHER
enrollment26
start date2026-11-01
primary completion2028-05-01
completion2028-05-01
results postednot reported

Conditions

  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory Mantle Cell Lymphoma

Interventions

  • Axicabtagene Ciloleucel
  • Biospecimen Collection
  • Brexucabtagene Autoleucel
  • Computed Tomography
  • Cyclophosphamide
  • Fludarabine
  • Natalizumab
  • Positron Emission Tomography

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG, PROCEDURE

Work with this record